ES2552803T3 - Composición farmacéutica novedosa que comprende un fármaco inmunosupresor macrólido - Google Patents
Composición farmacéutica novedosa que comprende un fármaco inmunosupresor macrólido Download PDFInfo
- Publication number
- ES2552803T3 ES2552803T3 ES10762917.2T ES10762917T ES2552803T3 ES 2552803 T3 ES2552803 T3 ES 2552803T3 ES 10762917 T ES10762917 T ES 10762917T ES 2552803 T3 ES2552803 T3 ES 2552803T3
- Authority
- ES
- Spain
- Prior art keywords
- pharmaceutical composition
- glycol
- tacrolimus
- novel pharmaceutical
- immunosuppressive drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003018 immunosuppressive agent Substances 0.000 title description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 title description 2
- 229940124589 immunosuppressive drug Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 abstract description 3
- 239000004530 micro-emulsion Substances 0.000 abstract description 3
- 229960001967 tacrolimus Drugs 0.000 abstract description 3
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 abstract description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- BUROJSBIWGDYCN-GAUTUEMISA-N AP 23573 Chemical compound C1C[C@@H](OP(C)(C)=O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 BUROJSBIWGDYCN-GAUTUEMISA-N 0.000 abstract 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 229960005167 everolimus Drugs 0.000 abstract 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 abstract 1
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 abstract 1
- 229960005330 pimecrolimus Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- 229960001302 ridaforolimus Drugs 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 229960000235 temsirolimus Drugs 0.000 abstract 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
- 229950009819 zotarolimus Drugs 0.000 abstract 1
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4055—Concentrating samples by solubility techniques
- G01N2001/4061—Solvent extraction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09012724A EP2308468A1 (en) | 2009-10-08 | 2009-10-08 | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
| EP09012724 | 2009-10-08 | ||
| PCT/EP2010/064965 WO2011042485A1 (en) | 2009-10-08 | 2010-10-07 | Novel pharmaceutical composition comprising a macrolide immunosuppressant drug |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2552803T3 true ES2552803T3 (es) | 2015-12-02 |
Family
ID=41435414
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10762917.2T Active ES2552803T3 (es) | 2009-10-08 | 2010-10-07 | Composición farmacéutica novedosa que comprende un fármaco inmunosupresor macrólido |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8574562B2 (enExample) |
| EP (2) | EP2308468A1 (enExample) |
| JP (1) | JP5764792B2 (enExample) |
| KR (1) | KR101790257B1 (enExample) |
| CN (1) | CN102510752B (enExample) |
| AU (1) | AU2010305404B2 (enExample) |
| BR (1) | BR112012007332B1 (enExample) |
| CA (1) | CA2774720C (enExample) |
| ES (1) | ES2552803T3 (enExample) |
| IN (1) | IN2012DN01559A (enExample) |
| MX (1) | MX2012003800A (enExample) |
| WO (1) | WO2011042485A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10265265B2 (en) | 2007-03-15 | 2019-04-23 | Drug Delivery Solutions Limited | Topical composition |
| TW201309306A (zh) * | 2011-06-23 | 2013-03-01 | 參天製藥股份有限公司 | 含有玻尿酸或其鹽及丙二醇之點眼液 |
| AU2014209141B2 (en) | 2013-01-24 | 2018-05-10 | Palvella Therapeutics, Inc. | Compositions for transdermal delivery of mTOR inhibitors |
| CN103830178B (zh) * | 2014-03-18 | 2017-01-11 | 深圳劲创生物技术有限公司 | 一种蒜氨酸微乳及其制备方法和应用 |
| US10525012B2 (en) * | 2015-08-11 | 2020-01-07 | Eyesiu Medicines B.V. | Pegylated lipid nanoparticle with bioactive lipophilic compound |
| JP6932180B2 (ja) * | 2016-04-04 | 2021-09-08 | エムシー２・セラピューティクス・リミテッドＭＣ２ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ | タクロリムスを含む局所組成物 |
| CN109310770A (zh) * | 2016-06-03 | 2019-02-05 | 埃维克辛公司 | 包含多不饱和酮和钙调磷酸酶抑制剂的联合疗法 |
| CN106074386A (zh) * | 2016-08-31 | 2016-11-09 | 佛山市弘泰药物研发有限公司 | 一种依维莫司自微乳制剂及其制备方法 |
| CA3037582A1 (en) | 2016-09-21 | 2018-03-29 | Avexxin As | Pharmaceutical composition |
| JP7108631B2 (ja) | 2017-01-06 | 2022-07-28 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物およびその使用方法 |
| EP3691654A4 (en) | 2017-09-25 | 2021-11-24 | Surface Pharmaceuticals, Inc. | OPHTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATMENT OF EYE SURFACE DISEASES |
| EP3542788A1 (en) | 2018-03-19 | 2019-09-25 | MC2 Therapeutics Limited | Topical composition comprising calcipotriol and betamethasone dipropionate |
| WO2019233722A1 (en) | 2018-06-08 | 2019-12-12 | Almirall, S.A. | Pharmaceutical composition comprising tacrolimus |
| JP2021530463A (ja) | 2018-07-02 | 2021-11-11 | パルヴェラ セラピューティクス、インク． | ｍＴＯＲ阻害剤の無水組成物および使用方法 |
| CA3124945A1 (en) | 2018-12-27 | 2020-07-02 | Surface Ophthalmics, Inc. | Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease |
| WO2021148619A1 (en) * | 2020-01-22 | 2021-07-29 | Bausch Health Ireland Limited | Topical compositions comprising a macrolide immunosuppressant |
| TWI769745B (zh) * | 2021-03-19 | 2022-07-01 | 國泰醫療財團法人國泰綜合醫院 | 醫藥組成物與製藥用途 |
| WO2022240598A1 (en) | 2021-05-10 | 2022-11-17 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| US12440510B2 (en) | 2021-05-10 | 2025-10-14 | Surface Ophthalmics, Inc. | Use of chondroitin sulfate for relieving ocular pain |
| BE1030538B1 (nl) | 2022-05-18 | 2023-12-19 | Bogaert Gina Van | Liposomaal preparaat met ingekapselde hormonen, werkwijze voor de productie en gebruik ervan |
| KR102727647B1 (ko) * | 2023-11-28 | 2024-11-08 | 장병모 | 칼시뉴린 억제제를 포함하는 피부질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26083A (en) * | 1987-11-09 | 1992-02-06 | Sandoz Ltd | 11, 28-dioxa-4-azatricyclo [22.3.1.04.9) octacos-18-ene derivatives and pharmaceutical compositions containing them and method of use thereof |
| KR0148748B1 (ko) * | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
| CH686761A5 (de) * | 1993-05-27 | 1996-06-28 | Sandoz Ag | Galenische Formulierungen. |
| GB2315216B (en) * | 1993-10-05 | 1998-10-14 | Ciba Geigy Ag | Microemulsion preconcentrates comprising FK506 or 33-epi-chloro-33-desoxy-ascomycin |
| EP0786986B1 (en) * | 1994-10-26 | 2002-03-20 | Novartis AG | Use of an unsaturated fatty alcohol |
| GB9723669D0 (en) * | 1997-11-07 | 1998-01-07 | Univ Aberdeen | Skin penetration enhancing components |
| DE10036871A1 (de) * | 2000-07-28 | 2002-02-14 | Pharmasol Gmbh | Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe |
| ATE468107T1 (de) * | 2001-11-01 | 2010-06-15 | Yissum Res Dev Co | Verfahren und zusammensetzung zur behandlung von trockenen augen |
| BR0117197A (pt) * | 2001-12-14 | 2004-12-14 | Jagotec Ag | Formulação de medicamento contendo ciclosporina aplicação do mesmo |
| JP2008506656A (ja) * | 2004-07-16 | 2008-03-06 | ノバルティス アクチエンゲゼルシャフト | 皮膚透過性の亢進のためのステロイドの使用 |
| EP1827373B1 (en) * | 2004-11-09 | 2008-12-03 | Novagali Pharma SA | Ophthalmic emulsions containing prostaglandins |
| KR100678829B1 (ko) * | 2004-12-06 | 2007-02-05 | 한미약품 주식회사 | 타크로리무스의 경구용 마이크로에멀젼 조성물 |
| EP1848407A2 (en) * | 2005-02-02 | 2007-10-31 | Mega Lifesciences Pvt. Ltd. | Oral pharmaceutical composition |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| GB2438544A (en) * | 2005-02-09 | 2007-11-28 | Cooper Internat Corp | Liquid formulations for treatment of diseases or conditions |
-
2009
- 2009-10-08 EP EP09012724A patent/EP2308468A1/en not_active Withdrawn
-
2010
- 2010-10-07 CA CA2774720A patent/CA2774720C/en active Active
- 2010-10-07 US US13/498,182 patent/US8574562B2/en active Active
- 2010-10-07 JP JP2012532587A patent/JP5764792B2/ja active Active
- 2010-10-07 KR KR1020127009028A patent/KR101790257B1/ko active Active
- 2010-10-07 WO PCT/EP2010/064965 patent/WO2011042485A1/en not_active Ceased
- 2010-10-07 CN CN201080042067.1A patent/CN102510752B/zh active Active
- 2010-10-07 EP EP10762917.2A patent/EP2485714B1/en active Active
- 2010-10-07 BR BR112012007332-0A patent/BR112012007332B1/pt active IP Right Grant
- 2010-10-07 MX MX2012003800A patent/MX2012003800A/es active IP Right Grant
- 2010-10-07 ES ES10762917.2T patent/ES2552803T3/es active Active
- 2010-10-07 AU AU2010305404A patent/AU2010305404B2/en active Active
-
2012
- 2012-02-21 IN IN1559DEN2012 patent/IN2012DN01559A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2774720A1 (en) | 2011-04-14 |
| BR112012007332A2 (pt) | 2016-10-04 |
| US20120184511A1 (en) | 2012-07-19 |
| CN102510752B (zh) | 2015-08-05 |
| CA2774720C (en) | 2017-05-23 |
| WO2011042485A1 (en) | 2011-04-14 |
| BR112012007332B1 (pt) | 2021-07-13 |
| JP5764792B2 (ja) | 2015-08-19 |
| CN102510752A (zh) | 2012-06-20 |
| EP2485714B1 (en) | 2015-09-09 |
| EP2485714A1 (en) | 2012-08-15 |
| KR20120093865A (ko) | 2012-08-23 |
| AU2010305404B2 (en) | 2015-04-02 |
| MX2012003800A (es) | 2012-06-28 |
| KR101790257B1 (ko) | 2017-10-26 |
| IN2012DN01559A (enExample) | 2015-06-05 |
| EP2308468A1 (en) | 2011-04-13 |
| AU2010305404A1 (en) | 2012-03-08 |
| JP2013507337A (ja) | 2013-03-04 |
| US8574562B2 (en) | 2013-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2552803T3 (es) | Composición farmacéutica novedosa que comprende un fármaco inmunosupresor macrólido | |
| US11491226B2 (en) | Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compound | |
| AU2018200079B2 (en) | Methods of Increasing Solubility of Poorly Soluble Compounds and Methods of Making and Using Formulations of Such Compounds | |
| JP2022180494A (ja) | 局所製剤 | |
| US10213443B2 (en) | Tetracycline topical formulations, preparation and uses thereof in treating an ocular condition | |
| JP2014511382A (ja) | フルマゼニル錯体、それを含む組成物、およびその使用 | |
| US11191704B2 (en) | Compositions and methods for controlled moisturizing and release of active ingredients | |
| JP2006522059A (ja) | 皮膚疾患の処置にて使用するための免疫抑制剤を含んでなる医薬組成物 | |
| JP6009791B2 (ja) | Ｈｄｃ活性化阻害剤、ｈｄｃ活性化阻害剤組成物、鎮痒剤及び鎮痒剤組成物 | |
| KR20230051117A (ko) | 로페콕시브를 함유하는 국소 조성물 및 이의 제조 및 사용 방법 | |
| US9593120B2 (en) | Paralytic shellfish poison | |
| WO2015179570A1 (en) | Waterborne topical compositions for the delivery of azelaic acid for treatment of skin conditions such as acne vulgaris, rosacea seborrheic dermatitis | |
| KR20070074624A (ko) | 매크롤라이드 ｔ-세포 면역조절물질 및 광노화방지제를포함하는 제약 조성물 | |
| CA3186628A1 (en) | Ror.gamma.t inhibitors and topical uses thereof | |
| ES2201074T3 (es) | Utilizacion topica o sistemica de buspirona o de derivados de esta para el tratamiento de trastornos patologicos asociados con reacciones inmunitarias. | |
| CA3159637A1 (en) | Ror gamma t inhibitors and topical uses thereof | |
| KR20230146630A (ko) | 아토피성 피부염 및 기타 피부 병태를 치료하기 위한 jak 1/3 억제제의 국소 제형 및 이의 사용 방법 | |
| US20190125880A1 (en) | Topical compositions for improved delivery of active agents | |
| CA3216947A1 (en) | Cyclosporine compositions and methods of use thereof | |
| JPH1179999A (ja) | 光線過敏症群治療剤 | |
| HK1205934B (en) | Paralytic shellfish poison for the treatment of itch |